Concerns over maternal and fetal drug exposures highlight the need for a better
understanding of drug distribution into the fetus through the placental barrier. This study …

Background Concerns over maternal and fetal drug exposure during pregnancy highlight
the need for improved understanding of drug distribution to the fetus through the placental …

Fetal exposure to drugs cannot be readily estimated from single time point cord blood
sampling at the time of delivery. Therefore, we developed a physiologically based …

Background: While physiologically based pharmacokinetic (PBPK) models generally predict
pharmacokinetics in pregnant women successfully, the confidence in predicting fetal …

Determining fetal drug exposure (except at the time of birth) is not possible for both logistical
and ethical reasons. Therefore, we developed a novel maternal-fetal physiologically based …

The unmet medical need of providing evidence‐based pharmacotherapy for pregnant
women is recognized by the regulatory bodies. Physiologically based pharmacokinetic …

Physiologically based pharmacokinetic modeling (PBPK) could be used to predict changes
in exposure during pregnancy and possibly inform medicine use in pregnancy in situations …

Background Since pregnant women are considerably underrepresented in clinical trials,
information on optimal dosing in pregnancy is widely lacking. Physiologically based …

Background: Drug prescriptions are usual during pregnancy, however, women and their
fetuses still remain an orphan population with regard to drugs efficacy and safety. Most …

Drugs can have harmful effects on the embryo or the fetus at any point during pregnancy.
Not all the damaging effects of intrauterine exposure to drugs are obvious at birth, some may …